The methionine/valine polymorphism at codon 129 of the prion protein gene shapes the neuropathology of genetic Creutzfeldt-Jakob disease caused by the E200K mutation, according to what its authors describe as the largest cohort of E200K cases analysed to date. The study, published in Acta Neuropathologica on 13 January 2026 by Brian Appleby, Ignazio Cali and colleagues at Case Western Reserve University and the National Prion Disease Pathology Surveillance Center in Cleveland, covered 177 individuals with codon 129 data resolved both by haplotype (the codon 129 residue carried on the same allele as the mutation) and by genotype. E200K is the most common pathogenic variant behind genetic CJD, which accounts for roughly 10 to 15 per cent of human prion disease.
The work was retrospective, drawing 181 E200K cases from the centre's brain bank and reviewing demographic, clinical, laboratory, histopathologic and molecular features, including western blot typing of the abnormal prion protein and real-time quaking-induced conversion (RT-QuIC) testing. Neuropathology was examined in 60 cases across all codon 129 genotypes, with 37 studied in more detail and 30 scored semi-quantitatively for spongiform change and gliosis; pathology reports from 90 further cases were reviewed. The authors identified five E200K subtypes associated with either prion protein type 1 or type 2, with other cases showing mixed prion protein types or mixed pathological features of the 129 M and 129 V haplotypes. Lesion profiles of the MM and MV genotypes were reported as virtually identical, while MV and VV differed in severity rather than distribution, and a fatal insomnia-like E200K phenotype differed significantly from the MM1 and MM2 subtypes.
On quantity of prion seeding activity, endpoint-dilution RT-QuIC on frontal cortex homogenates from representative cases found that seeding doses did not differ across E200K subtypes, including the fatal insomnia-like group. E200K frontal cortex seeding activity was reported as about tenfold higher than in the sporadic CJD cases tested, and up to 10,000-fold higher than in fatal insomnia cases. Brain MRI was positive for prion disease features in 70 per cent of the cohort, which the authors note is in line with the 75 per cent previously reported in genetic CJD.
The authors set out clear boundaries. Prion protein typing was done on a limited number of brain regions, which they say may underestimate how often mixed types occur, and the quantitative seeding measurements were performed on selected representative cases rather than the whole cohort. The series is also an autopsy-referral collection assembled through a national surveillance centre, not a prospective follow-up of gene carriers. Separately, a June 2025 Acta Neuropathologica study of 24 E200K cases from Slovakia, Spain and France, using transgenic mice expressing human prion protein, reported that E200K strains corresponded to the two most common sporadic CJD strains, sometimes as a mixture, supporting a similar role for codon 129 in strain selection.